EULAR evidence-based recommendations for the management of fibromyalgia syndrome

Academic Rheumatology Unit, King's College London, Weston Education Centre, Cutcombe Road, London SE5 9RJ, UK.
Annals of the rheumatic diseases (Impact Factor: 9.27). 05/2008; 67(4):536-41. DOI: 10.1136/ard.2007.071522
Source: PubMed

ABSTRACT To develop evidence-based recommendations for the management of fibromyalgia syndrome.
A multidisciplinary task force was formed representing 11 European countries. The design of the study, including search strategy, participants, interventions, outcome measures, data collection and analytical method, was defined at the outset. A systematic review was undertaken with the keywords "fibromyalgia", "treatment or management" and "trial". Studies were excluded if they did not utilise the American College of Rheumatology classification criteria, were not clinical trials, or included patients with chronic fatigue syndrome or myalgic encephalomyelitis. Primary outcome measures were change in pain assessed by visual analogue scale and fibromyalgia impact questionnaire. The quality of the studies was categorised based on randomisation, blinding and allocation concealment. Only the highest quality studies were used to base recommendations on. When there was insufficient evidence from the literature, a Delphi process was used to provide basis for recommendation.
146 studies were eligible for the review. 39 pharmacological intervention studies and 59 non-pharmacological were included in the final recommendation summary tables once those of a lower quality or with insufficient data were separated. The categories of treatment identified were antidepressants, analgesics, and "other pharmacological" and exercise, cognitive behavioural therapy, education, dietary interventions and "other non-pharmacological". In many studies sample size was small and the quality of the study was insufficient for strong recommendations to be made.
Nine recommendations for the management of fibromyalgia syndrome were developed using a systematic review and expert consensus.


Available from: Serena Carville, Jun 15, 2015
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Background The prevalence of fibromyalgia increases worldwide and is characterized by widespread and chronic pain. Treatment is difficult and includes both drug and non-drug approaches. Milnacipran, an antidepressant, is used for fibromyalgia, with a possible beneficial effect on central pain modulation. Our hypothesis is that the efficacy of milnacipran in fibromyalgia depends on the performance of pain inhibitory controls. Methods/design A randomized, double blind, clinical trial (NCT01747044) with two parallel groups, in 48 women with fibromyalgia, is planned in the Clinical Pharmacology Center, University Hospital, Clermont-Ferrand, France. Conditioned pain modulation (estimated with thermal stimuli using a numeric pain rating scale), the primary endpoint measure, is evaluated before and one month after treatment with milnacipran or placebo. Secondary outcome measures include the predictability of pain descending pathways performance for milnacipran efficacy, tolerance and cognitive function. Data analysis is performed using mixed models; the tests are two-sided, with a type I error set at alpha = 0.05. Not only will this trial allow estimation of the beneficial effect of milnacipran on pain and on descending pain pathways but it will also evaluate whether the performance of this modulatory system could be predictive of its efficacy in alleviating pain. Discussion This method would allow clinicians to take a pro-active attitude by performing a rapid psychophysical test before starting milnacipran treatment and would avoid unnecessary prescription while preventing therapeutic failure in patients who often face this recurrent problem. Trial registration NCT01747044.
    Trials 04/2015; 16(1). DOI:10.1186/s13063-015-0659-4 · 2.12 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The objective of the study was to develop evidence-based and practical recommendations for the detection and management of comorbidity in patients with rheumatoid arthritis (RA) in daily practice. We used a modified RAND/UCLA methodology and systematic review (SR). The process map and specific recommendations, based on the SR, were established in discussion groups. A two round Delphi survey permitted (1) to prioritize the recommendations, (2) to refine them, and (3) to evaluate their agreement by a large group of users. The recommendations cover: (1) which comorbidities should be investigated in clinical practice at the first and following visits (including treatments, risk factors and patient's features that might interfere with RA management); (2) how and when should comorbidities and risk factors be investigated; (3) how to manage specific comorbidities, related or non-related to RA, including major adverse events of RA treatment, and to promote health (general and musculoskeletal health); and (4) specific recommendations to assure an integral care approach for RA patients with any comorbidity, such as health care models for chronic inflammatory patients, early arthritis units, relationships with primary care, specialized nursing care, and self-management. These recommendations are intended to guide rheumatologists, patients, and other stakeholders, on the early diagnosis and management of comorbidity in RA, in order to improve disease outcomes.
    Rheumatology International 12/2014; 35(3). DOI:10.1007/s00296-014-3196-7 · 1.63 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: This study aimed to evaluate the efficacy of cognitive-behavioral therapy for insomnia (CBT-I) on polysomnographic parameters in patients with fibromyalgia (FM). Twenty-six women with FM participated in the study and were randomly assigned to a CBT-I (n = 13) group or sleep hygiene (SH) condition (n = 13). The evaluation consisted in two interview sessions and domiciliary polysomnography study before and after treatment. The results show that time-in-bed and wake percentage diminish after CBT-I. Improvements were also observed in sleep efficiency, which was close to normal levels. The percentage of NREM stage 1 sleep decreased and NREM stages 3 sleep and 4 increased. Similarly, light sleep (stages 1 and 2) diminished and deep sleep increased (stages 3 and 4) after CBT-I. No improvements were observed in any of these parameters in the individuals undergoing SH therapy. This randomized controlled trial provides new evidence that the use of CBT-I in FM patients can significantly improve objective sleep parameters. KEYWORDS. Fibromyalgia. Insomnia. Cognitive-behavioral therapy. Domiciliary polisomnography. Randomized controlled trial.
    International Journal of Clinical and Health Psychology 01/2012; 12(1):39-53. · 2.79 Impact Factor